ADCAN Pharma and MS Pharma forge strategic alliance to advance pharmaceutical localisation across the UAE
A landmark collaboration between two leading pharmaceutical enterprises promises to establish comprehensive biosimilar and biopharmaceutical manufacturing capabilities within the United Arab Emirates, positioning the nation as a regional centre of excellence in advanced therapeutic development.
A transformative strategic collaboration between ADCAN Pharma, a distinguished UAE-based pharmaceutical manufacturer, and MS Pharma, a prominent regional biopharmaceutical enterprise, has been announced to advance the localisation of biosimilars and pharmaceutical products throughout the United Arab Emirates. The partnership, unveiled during the prestigious Abu Dhabi Future Health Summit, underscores both organisations’ unwavering commitment to strengthening regional pharmaceutical manufacturing prowess, enhancing the affordability and accessibility of exceptional quality medicines, and guaranteeing robust supply chain continuity across the region.
The collaboration establishes a comprehensive framework encompassing local manufacturing, packaging, rigorous testing and batch release of biosimilars, injectable medicines and oral solid dosage forms within the UAE. The partnership demonstrates particular focus upon biosimilars, reflecting the increasingly vital role of advanced biologic therapies in addressing multifaceted chronic and complex disease presentations. The envisioned pharmaceutical portfolio spans diverse therapeutic domains including oncology, immunology, ophthalmology, respiratory conditions, metabolic and musculoskeletal disorders, anti-infective treatments, cardiovascular care, neurological medicine and genitourinary specialisms.
Dr. Fokion Sinis, Chief Executive Officer of ADCAN Pharma, emphasised the significance of this endeavour, observing that the partnership represents a defining advancement in pharmaceutical localisation within the UAE. Through this collaboration, ADCAN will establish a laboratory facility capable of executing the complete spectrum of quality testing procedures requisite for monoclonal antibodies, a milestone achievement in cultivating biosimilars technology, knowledge and testing expertise within the nation. By merging this sophisticated testing infrastructure with MS Pharma’s biopharmaceutical acumen, the partners endeavour to establish a sustainable, locally-driven biologics ecosystem that reinforces the UAE’s healthcare resilience and positions the nation prominently as a regional leader in sophisticated pharmaceutical manufacturing.
Ghandi Yacoub, Vice President Commercial at MS Pharma, reiterated the significance of expanding access to superior advanced treatments, positioning this as central to the enterprise’s mission of enhancing quality of life across regional communities. MS Pharma’s expanding biosimilar portfolio and biopharmaceutical expertise remain fundamental to this commitment, addressing unmet medical requirements and broadening therapeutic options. By synthesising these capabilities with ADCAN’s established manufacturing infrastructure and indigenous competencies, both entities aim to advance pharmaceutical localisation, deliver treatments with heightened proximity to patients and foster more sustainable healthcare systems throughout the region.
Through collaborative endeavour and systematic knowledge exchange, both organisations aspire to progressively expand local manufacturing capabilities, enhance patient access and contribute substantively to a more resilient and sustainable pharmaceutical sector. This partnership aligns harmoniously with the UAE’s healthcare and industrial development priorities, advancing pharmaceutical localisation, strengthening domestic manufacturing excellence and elevating the competitiveness of UAE-manufactured pharmaceutical products in both regional and global marketplaces.
Source: WAM